## Core Concept
d-Tubocurarine is a non-depolarizing neuromuscular blocking agent. It acts by competing with acetylcholine for receptors at the neuromuscular junction, thereby preventing depolarization of the muscle fiber. This class of drugs is commonly used in surgical procedures to facilitate endotracheal intubation and provide muscle relaxation.

## Why the Correct Answer is Right
The correct answer, **competitive antagonist of nicotinic acetylcholine receptors**, is right because d-tubocurarine works by binding to the nicotinic acetylcholine receptors at the neuromuscular junction. This prevents acetylcholine from binding to its receptors, which is necessary for muscle contraction. As a result, d-tubocurarine causes flaccid paralysis of skeletal muscles. The drug's mechanism involves a competitive inhibition, which can be overcome by increasing the concentration of acetylcholine.

## Why Each Wrong Option is Incorrect
- **Option A:** This option is incorrect because d-tubocurarine does not act as an agonist at nicotinic receptors; instead, it blocks the action of acetylcholine.
- **Option B:** This option is incorrect because d-tubocurarine does not primarily affect voltage-gated sodium channels; its action is more specific to the neuromuscular junction.
- **Option C:** This option might seem plausible because d-tubocurarine does affect neurotransmitter release indirectly by blocking receptors, but it is not described as enhancing GABAergic transmission.

## Clinical Pearl / High-Yield Fact
A key point to remember is that non-depolarizing neuromuscular blockers like d-tubocurarine can be reversed by anticholinesterase drugs (e.g., neostigmine), which increase acetylcholine levels in the synaptic cleft, thereby competing with the neuromuscular blocker for receptor sites.

## Correct Answer: . competitive antagonist of nicotinic acetylcholine receptors